AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Tenet Healthcare, you have to believe in a hospital operator that can convert steady, modest revenue growth into solid margins while managing a sizable debt load and ongoing capital needs. The latest Moody’s upgrade reinforces that the company’s balance sheet work and refinancing activity are being recognized, which could ease near term funding risk and support the extensive share buyback program. At the same time, Cantor Fitzgerald’s survey pointing to improving patient acuity ties directly into Tenet’s earnings profile, since higher acuity can support revenue and margin mix across its hospitals and outpatient assets. These updates may strengthen key short term catalysts around patient volumes, mix and interest expense, even as investors keep a close eye on forecast earnings declines, high leverage and recent insider selling.
However, one current risk that stands out may surprise some investors. Tenet Healthcare's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Explore 4 other fair value estimates on Tenet Healthcare - why the stock might be worth just $211.29!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com